The ectopic expression of MYADM was confirmed in non-small-cell lung cancer (NSCLC), acute promyelocytic leukemia, prostate cancer, colon cancer, melanoma, and pancreatic ductal adenocarcinoma 15,17-21. Here, MYADM is linked to prostate carcinoma.